​

Funding Round

Series B - Eliem Therapeutics

Series B - Eliem Therapeutics

Investment Firm

Overview

Eliem Therapeutics is a clinical-stage biotechnology company developing treatments for nervous system disorders.

Announced Date

May 24, 2021

Funding Type

Series B

Highlights

Location

United States, North America

Social

Investor Lead

Intermediate Capital Group

Intermediate Capital Group

Intermediate Capital Group is a debt and private_equity firm.

RA Capital Management

RA Capital Management

RA Capital Management is a convertible_note and debt and early_stage_venture and late_stage_venture and post_ipo and private_equity and seed and venture firm.

Participant Investors

5

Investor Name
Participant InvestorSamlyn Capital
Participant InvestorRA Capital Management
Participant InvestorIntermediate Capital Group
Participant InvestorAccess Biotechnology
Participant InvestorAcorn Bioventures

Round Details and Background

Eliem Therapeutics raised $60000000 on 2021-05-24 in Series B

Eliem Therapeutics is a clinical-stage biotechnology company developing treatments for nervous system disorders.

Company Funding History

7

Announcment DateTransaction NameNumber Of InvestorsLead InvestorMoney Raised
Mar 25, 2021
Series A - Eliem Therapeutics
3-80.0M
May 24, 2021
Series B - Eliem Therapeutics
6-60.0M
Apr 11, 2024
Post-IPO Equity - Eliem Therapeutics
6-120.0M
Jun 27, 2024
Post-IPO Equity - Eliem Therapeutics
1-120.0M

Recent Activity

There is no recent news or activity for this profile.